Summary

Overview
The Global Alcohol Use Disorder Treatment Market reached US$ XX million in 2022 and is expected to reach US$ XX million by 2030, growing with a CAGR of XX% during the forecast period 2023-2030.
Alcohol use disorder (AUD) is a medical illness marked by a decreased capacity to reduce or control alcohol consumption in the face of negative social, professional, or health effects. AUD is regarded as a neurological condition and can range in severity from mild to severe. Alcohol abuse causes long-lasting alterations in the brain that keep AUD alive and leave sufferers susceptible to relapse.
More people are seeking assistance as a result of increased awareness of AUD as a medical illness that may be treated. People are more likely to identify their issues and seek treatment as a result of the stigma associated with AUD being lessened. The number of possible treatments for AUD has increased due to the introduction of new drugs including naltrexone, acamprosate, and the more recent nalmefene.
Market Dynamics: Drivers
The Increasing Prevalence of Alcohol Use Disorder
In practically all of Europe, drinking alcohol is one of the major risk factors for injury and disease conditions. Aiming to lessen the harm caused by alcohol use, (inter)national policies and measures have been implemented in recent years. However, with 8.8% of adults aged 15 or older with AUD, the European Region continues to have the highest prevalence of AUD in the globe. Despite the significant frequency and detrimental effects of AUD, only 10% of those with AUD in Europe are believed to receive treatment.
In addition, in the United States, according to the 2021 National Survey on Drug Use and Health, 28.6 million adults over the age of 18 (11.3% of this age group) had AUD. An estimated 894,000 teenagers between the ages of 12 and 17 (3.4% of this age group) were thought to have AUD during this time. Alcohol use disorder is a serious issue in Canada because of the short- and long-term effects it has on people, their families, and their communities.
Furthermore, the increasing research activities drive the market. For instance, in April 2023, the effectiveness of psychedelic-assisted therapy for the treatment of alcohol consumption disorder (AUD) will soon be the subject of a study being conducted by researchers at Queen's University and Kingston Health Sciences Centre (KHSC). The Vancouver-based Clairvoyant Therapeutics-sponsored Phase 2b clinical trial will examine the efficacy of psilocybin use and motivational enhancement therapy for people with the illness.
Some varieties of mushrooms contain the naturally occurring chemical psilocybin, which has the ability to cause an altered state of consciousness. Although psilocybin has long been used for both spiritual and recreational purposes, there has recently been a resurgence in interest among scientists to investigate its efficacy in comparison to placebos. Researchers are particularly interested in determining whether providing patients with psychotherapy along with psilocybin is a secure and efficient method of treatment for a variety of medical disorders, including depression and AUD.
Limited Access to Treatment
Despite advancements, many people are still discouraged from getting treatment due to the stigma attached to AUD. The beginning of treatment may be hampered by denial of the issue. Geographical location, financial constraints, and a lack of skilled medical experts with expertise in addiction medicine are just a few of the variables that can limit access to AUD therapy. Access to care for AUD may be hampered by financial issues, including as the expense of care and a lack of insurance coverage.
Segment Analysis
The global alcohol use disorder treatment market is segmented based on disorder type, treatment type and region.
The medication segment accounted for approximately 43.5% of the market share
Naltrexone acts by lessening the reinforcement of alcohol consumption by endogenous opioids. Numerous studies have shown that naltrexone is beneficial in increasing the number of days of abstinence and continuous abstinence while decreasing the frequency of drinking days and median drinking days. Patients who also have an opioid use problem should be treated with caution when given naltrexone since the wrong dosage or timing of the medicine might cause severe opioid withdrawal.
Treatment for alcohol and opioid use disorders focuses on modifying the drugs' positive feedback loops that lead to euphoria. By inhibiting the mu-opioid receptor, naltrexone (and its active metabolite 6-beta-naltrexone) is pharmacologically efficient against alcohol.
The kappa and delta-opioid receptors are also less sensitive to naltrexone's antagonistic effects. By amplifying their effects, endogenous opioids play a role in regulating the effects of alcohol and opioids. By preventing opioid intoxication and physiologic dependence on opioid users, naltrexone suppresses the effects of opioids. To reduce ethanol intake, naltrexone alters the hypothalamic-pituitary-adrenal axis.
Geographical Analysis
North America segment accounted for approximately 42.6% of the market share
North America has been a dominant force in the global alcohol use disorder treatment market. Alcohol use disorder (AUD) continues to be a major problem in the US, affecting many people. Alcohol use disorder (AUD) is a common psychiatric illness in the United States that is characterized by unruly and harmful drinking habits. It is a widely recognized disorder that covers a wide range of signs and actions linked to alcohol abuse. One of the most common psychiatric disorders in the nation, AUD affects a sizeable section of the population. Alcohol abuse has effects on society as a whole, including social dynamics, economic factors, and public health, in addition to its effects on an individual's health.
The Centers for Disease Control and Prevention reports that every year, excessive alcohol use claims the lives of about 95,000 Americans, generally as a result of binge drinking or liver disease. it is also associated with significant economic and workplace losses, injury accidents, and deteriorated memory, learning, and mental health.
In July 2023, The National Institutes on Alcohol Abuse and Alcoholism (NIAAA) estimated that 16 million Americans suffer from alcohol use disorders (AUDs). Researchers at Indiana University have now achieved a significant advancement in our understanding of the role genes play in the emergence of AUDs, concluding that AUDs are more likely to result from alterations in a set of genes known to affect neuronal plasticity and pain perceptions than from a single gene defect.
As of July 2021, a dual-drug therapy for alcohol consumption disorder (AUD) has been developed by UC San Francisco researchers using two novel compounds, one of which is presently undergoing clinical oncology studies. This medication does not have the negative effects or consequences of other treatment options. The method produced excellent results in mice and might be useful for other medicines that are frequently abused. The team's fundamental hypothesis is that AUD and other substance misuse diseases arise through reinforced neural pathways in the brain, which may be blocked or redirected to eliminate cravings and repetitive behavior.
COVID-19 Impact Analysis
The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global Alcohol Use Disorder Treatment market. Healthcare services, especially centers for addiction treatment, were interrupted by the pandemic. People seeking treatment for AUD were impacted since many inpatient and outpatient treatment programs had to lower their capacity or temporarily close.
As a way to offer remote access to treatment, telehealth, and teletherapy grew more common, but not everyone could use these services. Research on AUD treatments and drugs was hampered by the pandemic, which might have slowed down advancement in this field.
By Disorder Type
• Alcohol Abuse
• Alcohol Dependence
• Alcohol Addiction
• Alcoholism
By Treatment Type
• Medication
o Opioid Receptor Antagonist
 Naltrexone
o Glutamate Agonist
 Acamprosate
o Alcohol Antagonist Drug
 Disulfiram
o Other Medications (Gabapentin and Topiramate)
• Multidisciplinary Treatment
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the market include Sobrera Pharma, Recipharm, Alkermes, Inc., ADial Pharmaceuticals, Inc., Addex Therapeutics, Kinnov Therapeutics, Opiant Pharmaceuticals Inc., and Omeros Corporation, Pfizer, Lundbeck and others.
Key Developments
• In October 2022, Opiant Pharmaceuticals Inc., a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, reported that the last patient has been enrolled in the Phase 2 clinical trial of OPNT002, nasal naltrexone, for patients with alcohol use disorder. The last patient to enroll is projected to finish the study in early 2023, and top-line data is anticipated to follow by the middle of the year.
Why Purchase the Report?
• To visualize the global alcohol use disorder treatment market segmentation based on product type, end-user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of alcohol use disorder treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global alcohol use disorder treatment market report would provide approximately 47 tables, 46 figures, and 186 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Disorder Type
3.2. Snippet by Treatment Type
3.3. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. The Increasing Prevalence of Alcohol Use Disorder
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. Limited Access to Treatment
4.1.2.2. XX
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Russia-Ukraine War Impact Analysis
5.6. SWOT Analysis
5.7. Patent Analysis
5.8. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Disorder Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disorder Type
7.1.2. Market Attractiveness Index, By Disorder Type
7.2. Alcohol Abuse*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Alcohol Dependence
7.4. Alcohol Addiction
7.5. Alcoholism
8. By End-user
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
8.1.2. Market Attractiveness Index, By End-user
8.2. Medication*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.2.3. Opioid Receptor Antagonist
8.2.3.1. Naltrexone
8.2.4. Glutamate Agonist
8.2.4.1. Acamprosate
8.2.5. Alcohol Antagonist Drug
8.2.5.1. Disulfiram
8.2.6. Other Medications (Gabapentin and Topiramate)
8.3. Multidisciplinary Treatment
8.4. Others
9. By Region
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disorder Type
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.5.1. U.S.
9.2.5.2. Canada
9.2.5.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disorder Type
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.5.1. Germany
9.3.5.2. UK
9.3.5.3. France
9.3.5.4. Italy
9.3.5.5. Spain
9.3.5.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disorder Type
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.5.1. Brazil
9.4.5.2. Argentina
9.4.5.3. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disorder Type
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.5.1. China
9.5.5.2. India
9.5.5.3. Japan
9.5.5.4. Australia
9.5.5.5. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disorder Type
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10. Competitive Landscape
10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis
11. Company Profiles
11.1.1. Sobrera Pharma*
11.1.2. Company Overview
11.1.3. Product Portfolio and Description
11.1.4. Financial Overview
11.1.5. Key Developments
11.2. Recipharm
11.3. Alkermes, Inc.,
11.4. ADial Pharmaceuticals, Inc.
11.5. Addex Therapeutics
11.6. Kinnov Therapeutics
11.7. Opiant Pharmaceuticals Inc.
11.8. Omeros Corporation
11.9. Pfizer
11.10. Lundbeck
LIST NOT EXHAUSTIVE
12. Appendix
12.1. About Us and Services
12.2. Contact Us